ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
|
|
Large accelerated filer ☐
|
|
Non-accelerated filer ☐
|
Emerging growth company
|
Smaller reporting company
|
•
|
Part I, Item 1A, Risk Factors
|
•
|
Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
•
|
Part II, Item 8, Financial Statements and Supplementary Data
|
•
|
Part II, Item 9A, Controls and Procedures
|
•
|
Part IV, Item 15, Exhibits and Financial Statement Schedules
|
Page
|
||
PART I
|
||
Item 1A.
|
4 |
|
PART II
|
||
Item 7.
|
20 | |
Item 8.
|
25 |
|
Item 9A.
|
48 |
|
PART IV
|
||
Item 15.
|
50 |
•
|
In the VirnetX Inc. v. Apple, Inc. (Case Nos. 6:11-cv-00563-RWS, 6:12-cv-00855-RWS) (“Apple II”) litigation, the United States Court of Appeals for the Federal Circuit (the “Federal Circuit”) in November
2019, affirmed-in-part, and reversed-in-part the judgment issued by the United States District Court for the Eastern District of Texas (the “district court”) in the case awarding VirnetX damages of $595.9 million. On October 30, 2020,
after a trial in the district court, a jury returned a verdict in favor of VirnetX, awarding VirnetX over $502 million in damages. On January 15, 2021, the district court denied Apple’s motion for judgment as a matter of law and
affirmed the jury findings. This may imply that VirnetX may soon receive over $500 million in cash, however, Apple has appealed to the Federal Circuit with regards to the judgement from the district court and this appeal is awaiting
calendaring for oral arguments. In addition, the patents in this case are being challenged in the United States Patent and Trademark Office. If those challenges are successful, the award in the case may be reduced, eliminated and/or
delayed for a lengthy period. The continuation of this litigation is distracting to our management, expensive, and these distractions and expenses may continue.
|
• |
We have undertaken activities to commercialize our products and patent portfolio in and outside the United States. These statements may imply that the worldwide market for our commercialized products is large
and will result in significant future revenues for us. However, commercialization of products such as ours is subject to significant obstacles and risks, including but not limited to a perception by some potential partners and customers
that they should await the outcome of the Apple II litigation before entering or considering to enter any agreement with us, and that or other factors may lead us to be unsuccessful in obtaining further licensing agreements or making
arrangements or entering contracts which create significant future revenues for us.
|
Item 1A. |
Risk Factors
|
•
|
We are involved and will continue to be involved in litigation defending our patent portfolio, which can be time-consuming and costly,
and we cannot anticipate the results.
|
|
•
|
We may not be able to capitalize on market opportunities related to our licensing strategy or our patent portfolio.
|
|
•
|
If we are not able to adequately protect our patent rights, our business would be negatively impacted.
|
|
•
|
Because our business is conducted or expected to be conducted in an environment that is subject to rapid change, we may be subject to
various developments in regulation, law, and consumer preferences to which we may not be able to adapt successfully.
|
|
•
|
Our exposure to outside influences beyond our control, including new legislation, court rulings or actions by the United States Patent
and Trademark Office, could adversely affect our licensing and enforcement activities and results of operations.
|
|
•
|
New legislation, regulations or court rulings related to enforcing patents could harm our business and operating results.
|
|
•
|
Privacy and data security concerns, and data collection and transfer restrictions and related domestic or foreign regulations may limit the use and adoption of our solutions and adversely affect our
business.
|
|
•
|
If we are unable to expand our revenue sources or establish, sustain, grow, or replace relationships with a diversified customer base,
our revenues may be limited.
|
|
•
|
We have limited technical resources and are at an early stage in commercialization of our software products.
|
|
•
|
Our international expansion will subject us to additional costs and risks, and our plans may not be successful.
|
|
•
|
We have had to restate our previously issued consolidated financial statements and as part of that process have identified a material
weakness in our internal control over financial reporting as of December 31, 2021. If we are unable to develop and maintain an effective system of internal control over financial reporting, we may not be able to accurately report our
financial results in a timely manner, which may adversely affect investor confidence in us and materially and adversely affect our business and operating results.
|
|
•
|
We may face litigation and other risks as a result of the restatement and material weakness in our internal control over financial
reporting.
|
• |
Third parties may challenge the validity of our patents;
|
• |
The pendency of our various litigations may cause potential licensees not to do business with us;
|
• |
Our patents may expire before we can make our business strategy successful;
|
• |
We face, and we expect to continue to face, intense competition from new and established competitors who may have superior products and services or better marketing, financial or other capacities than we do; and
|
• |
It is possible that one or more of our potential customers or licensees develops or otherwise sources products or technologies similar to, competitive with or superior to ours.
|
• |
New legislation, regulations or rules related to obtaining patents or enforcing patents could significantly increase our operating costs and decrease our revenue. For instance, the United States Supreme Court has modified some tests
used by the USPTO in granting patents during the past 20 years which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge of any patents we obtain or license. In addition, in 2012 the
United States enacted sweeping changes to the United States patent system under the Leahy-Smith America Invents Act, including changes that transition the United States from a “first-to-invent” system to a “first to file” system and alter
the processes for challenging issued patents;
|
• |
More patent applications are filed each year resulting in longer delays in getting patents issued by the USPTO;
|
• |
Federal courts are becoming more crowded, and as a result, patent enforcement litigation is taking longer; and
|
• |
As patent enforcement becomes more prevalent, it may become more difficult for us to voluntarily license our patents.
|
• |
The need to educate potential customers about our patent rights and our product and service capabilities;
|
• |
The impact of the COVID-19 pandemic on our potential customers and their business operations, including their budgetary constraints and resources devoted to adopting new products.
|
• |
Our customers’ willingness to invest potentially substantial resources and modify their network infrastructures to take advantage of our products;
|
• |
Our customers’ budgetary constraints;
|
• |
The timing of our customers’ budget cycles;
|
• |
Delays caused by customers’ internal review processes; and
|
• |
Long sales cycles that may increase the risk that our financial resources are exhausted before we are able to generate significant revenue.
|
• |
Generate revenues or profit from product sales;
|
• |
Drive adoption of our products;
|
• |
Attract and retain customers for our products;
|
• |
Provide appropriate levels of customer training and support for our products;
|
• |
Implement an effective marketing strategy to promote awareness of our products;
|
• |
Focus our research and development efforts in areas that generate returns on our efforts;
|
• |
Anticipate and adapt to changes in our market; or
|
• |
Protect our products from any system failures or other breaches.
|
• |
Power loss, transmission cable cuts and other telecommunications failures;
|
• |
Damage or interruption caused by fire, earthquake, and other natural disasters;
|
• |
Computer viruses or software defects; and
|
• |
Physical or electronic break-ins, sabotage, intentional acts of vandalism, terrorist attacks and other events beyond our control.
|
• |
A staggered Board of Directors: This means that only one or two directors (since we have a five-person Board of Directors) will be up for election at any given annual meeting. This has the effect
of delaying the ability of stockholders to affect a change in control of us because it would take two annual meetings to effectively replace a majority of the Board of Directors.
|
• |
Blank check preferred stock: Our Board of Directors has the authority to establish the rights, preferences, and privileges of our 10,000,000 authorized, but unissued, shares of preferred stock.
Therefore, this stock may be issued at the discretion of our Board of Directors with preferences over your shares of our common stock in a manner that is materially dilutive to you. In addition, blank check preferred stock can be used to
create a “poison pill” which is designed to deter a hostile bidder from buying a controlling interest in our stock without the approval of our Board of Directors. We have not adopted such a “poison pill;” but our Board of Directors has the
ability to do so in the future, very rapidly and without stockholder approval.
|
• |
Advance notice requirements for director nominations and for new business to be brought up at stockholder meetings: Stockholders wishing to submit director nominations or raise matters to a vote
of the stockholders must provide notice to us within very specific date windows and in very specific form in order to have the matter voted on at a stockholder meeting. This has the effect of giving our Board of Directors and management
more time to react to stockholder proposals generally and could also have the effect of disregarding a stockholder proposal or deferring it to a subsequent meeting to the extent such proposal is not raised properly.
|
• |
No stockholder actions by written consent: No stockholder or group of stockholders may take actions rapidly and without prior notice to our Board of Directors and management or to the minority
stockholders. Along with the advance notice requirements described above, this provision also gives our Board of Directors and management more time to react to proposed stockholder actions.
|
• |
Super majority requirement for stockholder amendments to the bylaws: Stockholder proposals to alter or amend our bylaws or to adopt new bylaws can only be approved by the affirmative vote of at
least 66 2/3% of the outstanding shares of our common stock.
|
• |
No ability of stockholders to call a special meeting of the stockholders: Only the Board of Directors or management can call special meetings of the stockholders. This could mean that
stockholders, even those who represent a significant percentage of our shares of common stock, may need to wait for the annual meeting before nominating directors or raising other business proposals to be voted on by the stockholders.
|
• |
Developments or lack thereof in any then-outstanding litigation;
|
• |
Quarterly variations in our operating results;
|
• |
Large purchases or sales of common stock or derivative transactions related to our stock;
|
• |
Actual or anticipated announcements of new products or services by us or competitors;
|
• |
General conditions in the markets in which we compete; and
|
• |
General social, political, economic, and financial conditions, including the significant volatility in the global financial markets, and impacts from the COVID-19 pandemic.
|
• |
Price and volume fluctuations in the overall stock market from time to time, including fluctuations due to general economic uncertainty or negative market sentiment;
|
• |
Volatility in the market prices and trading volumes of companies in our industry or companies that investors consider comparable;
|
• |
Changes in operating performance and stock market valuations of other companies generally, or those in our industry;
|
• |
Sales of shares of our common stock by us or our stockholders;
|
• |
Failure of securities analysts to maintain coverage of us, changes in financial estimates by securities analysts who follow us, or our failure to meet these estimates or the expectations of investors;
|
• |
The financial projections we may provide to the public, any changes in those projections or our failure to meet those projections;
|
• |
Announcements by us or our competitors of new products or services;
|
• |
The public’s reaction to our press releases, other public announcements, and filings with the SEC;
|
• |
Rumors and market speculation involving us or other companies in our industry;
|
• |
Actual or anticipated changes in our results of operations;
|
• |
Actual or anticipated developments in our business, our competitors’ businesses, or the competitive landscape generally;
|
• |
Litigation involving us, our industry or both, or investigations by regulators into our operations or those of our competitors;
|
• |
Announced or completed acquisitions of businesses or technologies by us or our competitors;
|
• |
New laws or regulations or new interpretations of existing laws or regulations applicable to our business;
|
• |
Changes in accounting standards, policies, guidelines, interpretations, or principles;
|
• |
Any significant change in our management; and
|
• |
General economic conditions and slow or negative growth of our markets, including any economic downturn from the COVID-19 pandemic.
|
• |
The outcome of actions to enforce our intellectual property rights currently in progress or that we may undertake in the future, and the timing thereof;
|
• |
The impact of the COVID-19 pandemic on our sales cycle and results;
|
• |
The amount and timing of receipt of license fees from potential infringers, licensees, or customers;
|
• |
The rate of adoption of our patented technologies;
|
• |
The number of new license arrangements we may execute, or that may expire, within a particular period and the scope of those licenses, including the number of our patents which are licensed, the extent of prior infringement of our patent
rights, royalty rates, timing of payment obligations, expiration date etc.;
|
• |
The success of a licensee in selling products that use our patented technologies; and
|
• |
The amount and timing of expenses related to our patent filings and enforcement proceedings, including litigation, related to our intellectual property rights.
|
Item 7. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations
|
2021
|
2020
|
2019
|
||||||||||
Revenue
|
$
|
35
|
$
|
302,636
|
$
|
85
|
2021
|
2020
|
2019
|
||||||||||
Licensing costs
|
$
|
(9,083
|
)
|
$
|
90,101
|
$
|
—
|
2021
|
2020
|
2019
|
||||||||||
Research and Development
|
$
|
5,557
|
$
|
8,830
|
$
|
3,845
|
2021
|
2020
|
2019
|
||||||||||
Selling, General and Administrative
|
$
|
52,715
|
$
|
45,812
|
$
|
15,905
|
2021
|
2020
|
2019
|
||||||||||
Interest and Other Income
|
$
|
48
|
$
|
108,288
|
$
|
92
|
|
As restated
Year Ended
December 31, 2021
|
Year Ended
December 31, 2020
|
Year Ended
December 31, 2019
|
|||||||||
United States federal statutory rate
|
21.00
|
%
|
21.00
|
%
|
21.00
|
%
|
||||||
State taxes, net of federal benefit
|
(0.31
|
)%
|
0.17
|
%
|
1.99
|
%
|
||||||
Valuation allowance
|
—
|
(12.22
|
)%
|
(21.96
|
)%
|
|||||||
Stock based compensation
|
(6.68
|
)%
|
(0.01
|
)%
|
—
|
|||||||
R&D credit
|
0.19
|
%
|
(0.21
|
)%
|
1.34
|
%
|
||||||
Other
|
(1.57
|
)%
|
0.06
|
%
|
(0.38
|
)%
|
||||||
Effective income tax rate
|
12.63
|
%
|
8.79
|
%
|
1.99
|
%
|
Deferred Taxes
|
||
Description of the Matter
|
As discussed in Notes 2 and 10 to the financial statements, the Company recorded a deferred tax asset, net of a valuation
allowance as of December 31, 2021. In assessing the ability to realize the deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will
not be realized. The valuation allowance is based on management’s estimates of future taxable income and application of relevant income tax law.
Our determination that valuation of deferred taxes is a critical audit matter results from the significant judgment by management when assessing the ability to realize the deferred tax assets, particularly as it relates to estimates of future taxable income. This in turn led to a high
degree of auditor judgment, subjectivity, and effort in performing procedures relating to management’s assessment of the realizability of deferred tax assets, as it relates to estimates of future taxable income and application of income
tax law.
|
|
|
|
|
Audit Procedures
|
Our principal audit procedures related to the Company’s deferred taxes included the following: | |
- |
We evaluated management’s assessment of the realizability of deferred tax assets on a jurisdictional basis. This included
evaluating estimates of future taxable income, evaluating management’s application of income tax law, and testing the completeness and accuracy of underlying data used in management’s assessment.
|
|
- |
We evaluated management’s estimates of future taxable income which involved evaluating whether the estimates used by management
were reasonable considering the current and past performance of the respective entity and whether the estimates were consistent with evidence obtained in other areas of the audit.
|
As restated
As of
December 31, 2021
|
As of
December 31, 2020
|
|||||||
ASSETS
|
||||||||
Current assets:
|
||||||||
Cash and cash equivalents
|
$
|
|
$
|
|
||||
Investments available for sale
|
|
|
||||||
Accounts receivables
|
|
|
||||||
Prepaid income tax
|
|
|
||||||
Prepaid expenses and other current assets
|
|
|
||||||
Total current assets
|
|
|
||||||
Prepaid expenses and other assets
|
|
|
||||||
Property and equipment, net
|
|
|
||||||
Deferred tax asset
|
|
|
||||||
Total assets
|
$
|
|
$
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable and accrued liabilities
|
$
|
|
$
|
|
||||
Accrued payroll and related expenses
|
|
|
||||||
Accrued licensing costs
|
|
|
||||||
Other liabilities, current
|
|
|
||||||
Total current liabilities
|
|
|
||||||
Other liabilities
|
|
|
||||||
Total liabilities
|
|
|
||||||
Commitments and contingencies (Note 4)
|
|
|
||||||
Stockholders’ equity:
|
||||||||
Preferred stock, par value $
|
|
|
||||||
Common stock, par value $
|
||||||||
Authorized:
|
|
|
||||||
Additional paid-in capital
|
|
|
||||||
Accumulated deficit
|
(
|
)
|
(
|
)
|
||||
Accumulated other comprehensive loss
|
(
|
)
|
(
|
)
|
||||
Total stockholders’ equity
|
|
|
||||||
Total liabilities and stockholders’ equity
|
$
|
|
$
|
|
|
As restated
Year Ended
December 31, 2021
|
Year Ended
December 31, 2020
|
Year Ended
December 31, 2019
|
|||||||||
Revenue
|
$
|
|
$
|
|
$
|
|
||||||
Operating expense:
|
||||||||||||
Licensing costs
|
(
|
)
|
|
|
||||||||
Research and development
|
|
|
|
|||||||||
Selling, general and administrative expenses
|
|
|
|
|||||||||
Total operating expense
|
|
|
|
|||||||||
(Loss) income from operations
|
(
|
)
|
|
(
|
)
|
|||||||
Gain on settlement
|
|
|
|
|||||||||
Interest and other income, net
|
|
|
|
|||||||||
(Loss) income before taxes
|
(
|
)
|
|
(
|
)
|
|||||||
Income tax benefit (provision)
|
|
(
|
)
|
|
||||||||
Net (loss) income
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
||||
Basic (loss) earnings per share
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
||||
Diluted (loss) earnings per share
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
||||
Weighted average shares outstanding basic
|
|
|
|
|||||||||
Weighted average shares outstanding diluted
|
|
|
|
|
As restated
Year Ended
December 31, 2021
|
Year Ended
December 31, 2020
|
Year Ended
December 31, 2019
|
|||||||||
Net (loss) income
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
||||
Other comprehensive (loss) income, net of tax:
|
||||||||||||
Change in unrealized (loss) gain on investments, net
|
(
|
)
|
|
|
||||||||
Change in foreign currency translation, net
|
(
|
)
|
|
(
|
)
|
|||||||
Total other comprehensive (loss) gain, net of tax
|
(
|
)
|
|
|
||||||||
Comprehensive (loss) income
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
As restated
Year Ended
December 31, 2021
|
Year Ended
December 31, 2020
|
Year Ended
December 31, 2019
|
||||||||||
Total shareholders’ equity, beginning balances
|
$
|
|
$
|
|
$
|
|
||||||
Common stock and additional paid-in capital:
|
||||||||||||
Beginning balances
|
|
|
|
|||||||||
Common stock issued for cash, net
|
|
|
|
|||||||||
Common stock issued for options/RSUs, net
|
(
|
)
|
|
|
||||||||
Warrants issued for services
|
|
|
|
|||||||||
Stock-based compensation
|
|
|
|
|||||||||
Ending balances
|
|
|
|
|||||||||
Accumulated deficit (retained earnings)
|
||||||||||||
Beginning balances
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Net (loss) income
|
(
|
)
|
|
(
|
)
|
|||||||
Dividends
|
|
(
|
)
|
|
||||||||
Ending balances
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Accumulated other comprehensive loss:
|
||||||||||||
Beginning balances
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Change in unrealized investment (loss) gain, net
|
(
|
)
|
|
|
||||||||
Change in foreign currency translation, net
|
(
|
)
|
|
(
|
)
|
|||||||
Ending balances
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Total shareholders’ equity, ending balances
|
$
|
|
$
|
|
$
|
|
||||||
Dividends per share
|
$ | $ | $ |
|
As restated
Year Ended
December 31, 2021
|
Year Ended
December 31, 2020
|
Year Ended
December 31, 2019
|
|||||||||
Cash flows from operating activities:
|
||||||||||||
Net (loss) income
|
$
|
(
|
)
|
$
|
|
$
|
(
|
)
|
||||
Adjustments to reconcile net (loss) income to
net cash from operating activities:
|
||||||||||||
Depreciation
|
|
|
|
|||||||||
Stock-based compensation
|
|
|
|
|||||||||
Amortization of warrants issuance costs
|
|
|
|
|||||||||
Deferred income taxes
|
(
|
)
|
(
|
)
|
|
|||||||
Changes in assets and liabilities:
|
||||||||||||
Prepaid expenses and other current assets
|
|
|
|
|||||||||
Accounts payable and accrued liabilities
|
(
|
)
|
(
|
)
|
|
|||||||
Other liabilities
|
|
(
|
)
|
|
||||||||
Accrued payroll and related expenses
|
|
(
|
)
|
|
||||||||
Accrued licensing costs
|
(
|
)
|
|
|
||||||||
Accounts receivable
|
(
|
)
|
(
|
)
|
|
|||||||
Prepaid income taxes
|
|
(
|
)
|
(
|
)
|
|||||||
Net cash (used in) provided by operating activities
|
(
|
)
|
|
(
|
)
|
|||||||
Cash flows from investing activities:
|
||||||||||||
Purchase of property and equipment
|
(
|
)
|
|
(
|
)
|
|||||||
Purchase of investments
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Proceeds from sale or maturity of investments
|
|
|
|
|||||||||
Net cash provided by (used in) investing activities
|
|
(
|
)
|
(
|
)
|
|||||||
Cash flows from financing activities:
|
||||||||||||
Proceeds from exercise of options
|
|
|
|
|||||||||
Proceeds from sale of common stock
|
|
|
|
|||||||||
Dividends paid on common stock
|
|
(
|
)
|
|
||||||||
Taxes paid on cashless exercise of restricted stock units
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Net cash (used in) provided by financing activities
|
(
|
)
|
(
|
)
|
|
|||||||
Net (decrease) increase in cash and cash equivalents
|
(
|
)
|
|
(
|
)
|
|||||||
Cash and cash equivalents, beginning of period
|
|
|
|
|||||||||
Cash and cash equivalents, end of period
|
$
|
|
$
|
|
$
|
|
||||||
Cash paid for income taxes
|
$
|
|
$
|
|
$
|
|
As of and for the year ended
December 31, 2021
|
||||||||||||
As Previously Reported
|
Restatement Adjustment
|
As Restated
|
||||||||||
Consolidated Balance Sheet
|
||||||||||||
Deferred tax asset
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||
Total assets
|
|
(
|
)
|
|
||||||||
Accumulated deficit
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Total stockholders’ equity
|
|
(
|
)
|
|
||||||||
Total liabilities and stockholders’ equity
|
|
(
|
)
|
|
||||||||
Consolidated Statement of Operations
|
||||||||||||
Income tax benefit
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||
Net loss
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Basic loss per share
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Diluted loss per share
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Consolidated Statement of Comprehensive Loss
|
||||||||||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Comprehensive loss
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Consolidated Statement of Stockholders’ Equity
|
||||||||||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Ending balance, accumulated deficit
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Total liabilities and stockholders’ equity
|
|
(
|
)
|
|
||||||||
Consolidated Statement of Cash Flows
|
||||||||||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Deferred income taxes
|
(
|
)
|
|
(
|
)
|
|||||||
Note 7 - Earnings per share
|
||||||||||||
Net loss
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Basic loss per share
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Diluted loss per share
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Note 10 - Income Taxes, income tax provision
|
||||||||||||
Deferred income tax benefit, Federal
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
(
|
)
|
|||
Deferred income tax benefit, State
|
|
|
|
|||||||||
Total deferred income tax benefit
|
(
|
)
|
(
|
)
|
(
|
)
|
||||||
Total income tax benefit
|
(
|
)
|
|
(
|
)
|
|||||||
Note 10 - Income Taxes, reconciliation of income tax rate
|
||||||||||||
State taxes, net of federal benefit
|
(
|
)%
|
(
|
)%
|
(
|
)%
|
||||||
Stock based compensation
|
(
|
)%
|
(
|
)%
|
(
|
)%
|
||||||
Effective income tax rate
|
|
%
|
(
|
)%
|
|
%
|
||||||
Note 10 - Income Taxes, deferred tax assets
|
||||||||||||
Stock based compensation
|
$
|
|
$
|
(
|
)
|
$
|
|
|||||
Total deferred tax assets
|
|
(
|
)
|
|
||||||||
Deferred tax assets after valuation allowance
|
|
(
|
)
|
|
||||||||
Net deferred tax assets
|
( |
) |
Classification of Payment Received in the Company’s Condensed Consolidated Statement of Operations Year Ended:
|
||||
December 31, 2020
|
||||
Revenue (royalties)
|
$
|
|
||
Operating expenses: selling, general and administrative (reimbursed litigation costs)
|
|
|||
Other income: gain (willful infringement)
|
|
|||
Other income: interest income (pre- and post-judgment interest)
|
|
|||
Total cash received
|
$
|
|
December 31
|
||||||||
2021
|
2020
|
|||||||
Office furniture
|
$
|
|
$
|
|
||||
Computer equipment
|
|
|
||||||
Total
|
|
|
||||||
Less accumulated depreciation
|
(
|
)
|
(
|
)
|
||||
Total property and equipment, net
|
$
|
|
$
|
|
Options Outstanding
|
Options Vested and Exercisable
|
|||||||||||||||||||||||
Range of
Exercise Prices |
Number
Outstanding
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Weighted
Average
Exercise
Price
|
Number
Exercisable
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Weighted
Average
Exercise
Price
|
||||||||||||||||||
$
|
|
|
$
|
|
|
|
$
|
|
||||||||||||||||
$
|
|
|
$
|
|
|
|
$
|
|
||||||||||||||||
|
|
$
|
|
|
|
$
|
|
Options
|
||||||||||||||||
Number of
Shares
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Aggregate
Intrinsic
Value
|
|||||||||||||
Outstanding at December 31, 2018 | $ |
— | $ |
— | ||||||||||||
Options granted | — | — | ||||||||||||||
Options exercised | ( |
) | — | — | ||||||||||||
Options cancelled | ( |
) | — | — | ||||||||||||
Outstanding at December 31, 2019
|
|
$
|
|
—
|
$
|
—
|
||||||||||
Options granted
|
|
|
—
|
—
|
||||||||||||
Options exercised
|
(
|
)
|
|
—
|
—
|
|||||||||||
Options cancelled
|
(
|
)
|
|
—
|
—
|
|||||||||||
Outstanding at December 31, 2020
|
|
$
|
|
—
|
$
|
|
||||||||||
Options granted
|
|
|
—
|
—
|
||||||||||||
Options exercised
|
|
|
—
|
—
|
||||||||||||
Options cancelled
|
(
|
)
|
|
—
|
—
|
|||||||||||
Outstanding at December 31, 2021
|
|
$
|
|
|
$
|
|
||||||||||
Options exercisable at December 31, 2021
|
|
$
|
|
|
$
|
|
RSUs
|
||||||||||||
Number of
RSUs
|
Weighted
Average
Grant Date
Fair Value
|
Aggregate
Intrinsic
Value
|
||||||||||
Outstanding at December 31, 2018 | $ | $ | ||||||||||
RSUs granted | — |
|||||||||||
RSUs vested | ( |
) | — |
|||||||||
RSUs cancelled | ( |
) | — | |||||||||
Outstanding at December 31, 2019
|
|
$
|
|
$
|
|
|||||||
RSUs granted
|
|
|
—
|
|||||||||
RSUs vested
|
(
|
)
|
|
—
|
||||||||
RSUs cancelled
|
|
|
—
|
|||||||||
Outstanding at December 31, 2020
|
|
$
|
|
$
|
|
|||||||
RSUs granted
|
|
|
—
|
|||||||||
RSUs vested
|
(
|
)
|
|
—
|
||||||||
RSUs cancelled |
( |
) | — | |||||||||
Outstanding at December 31, 2021
|
|
$
|
|
$
|
|
Stock-Based Compensation by Type of Award
|
Year Ended
December 31, 2021
|
Year Ended
December 31, 2020
|
Year Ended
December 31, 2019
|
|||||||||
Stock options
|
$
|
|
$
|
|
$ |
|||||||
RSUs
|
|
|
||||||||||
Total stock-based compensation expense
|
$
|
|
$
|
|
$ |
Year Ended
December 31, 2021
|
Year Ended
December 31, 2020
|
Year Ended
December 31, 2019
|
||||||||||
Expected stock price volatility
|
|
%
|
|
%
|
% | |||||||
Risk-free interest rate
|
|
%
|
|
%
|
% | |||||||
Expected life term
|
|
|
||||||||||
Expected dividends
|
|
%
|
|
%
|
% |
As restated
Year Ended
December 31, 2021
|
Year Ended
December 31, 2020
|
Year Ended
December 31, 2019
|
||||||||||
Net (loss) income
|
$
|
(
|
)
|
$
|
|
$ |
( |
) | ||||
Basic weighted average number of shares outstanding
|
||||||||||||
Effect of dilutive securities
|
|
|
||||||||||
Diluted weighted average number of shares outstanding
|
|
|
||||||||||
Basic (loss) earnings per share
|
$
|
(
|
)
|
$
|
|
$ |
( |
) | ||||
Diluted (loss) earnings per share
|
$
|
(
|
)
|
$
|
|
$ |
( |
) |
Warrants Issued
|
Exercise
Price
|
Outstanding and
Exercisable
December 31, 2020
|
Issued
|
Exercised
|
Terminated /
Cancelled
|
Outstanding and
Exercisable
December 31, 2021
|
Expiration Date
|
|||||||
|
$
|
|
|
|
|
|
|
As restated
Year Ended
December 31, 2021 |
Year Ended
December 31, 2020 |
Year Ended December 31, 2019 |
||||||||||
Current:
|
||||||||||||
Federal
|
$
|
|
$
|
|
$ | |||||||
State
|
|
|
( |
) | ||||||||
Foreign | ||||||||||||
|
|
( |
) | |||||||||
Deferred:
|
||||||||||||
Federal
|
(
|
)
|
(
|
)
|
||||||||
State
|
|
(
|
)
|
|||||||||
( |
) | ( |
) | |||||||||
Total income tax (benefit) provision
|
$ | ( |
) |
$
|
|
$ | ( |
) |
As restated
Year Ended
December 31, 2021 |
Year Ended
December 31, 2020 |
Year Ended December 31, 2019 |
||||||||||
United States federal statutory rate
|
|
%
|
|
%
|
% | |||||||
State taxes, net of federal benefit
|
(
|
)%
|
|
%
|
% | |||||||
Valuation allowance
|
|
(
|
)%
|
( |
)% | |||||||
Stock based compensation
|
(
|
)%
|
(
|
)%
|
||||||||
R&D Credit
|
|
%
|
(
|
)%
|
% | |||||||
Other
|
(
|
)%
|
|
%
|
( |
)% | ||||||
Effective income tax rate
|
% |
|
%
|
% |
As restated
As of
December 31, 2021 |
As of
December 31, 2020 |
|||||||
Deferred tax assets:
|
||||||||
Reserves and accruals
|
$
|
|
$
|
|
||||
Research and development credits and other credits
|
|
|
||||||
Net operating loss carry forward
|
|
|
||||||
Stock based compensation
|
|
|
||||||
Other
|
|
|
||||||
Total deferred tax assets
|
$
|
|
$
|
|
||||
Valuation allowance
|
|
(
|
)
|
|||||
Deferred tax assets after valuation allowance
|
|
|
||||||
Total deferred tax liability – depreciation
|
(
|
)
|
|
|||||
Net deferred tax assets
|
$
|
|
$
|
|
December 31, 2021
|
||||||||||||||||||||||||
Adjusted
Cost |
Unrealized
Gains |
Unrealized
Losses |
Fair
Value |
Cash
and Cash Equivalents |
Investments
Available for Sale |
|||||||||||||||||||
Cash
|
$
|
|
$
|
—
|
$
|
—
|
$
|
|
$
|
|
$
|
—
|
||||||||||||
Level 1:
|
||||||||||||||||||||||||
Mutual funds
|
|
|
|
|
|
|
||||||||||||||||||
U.S. agency securities
|
|
|
(
|
)
|
|
|
|
|||||||||||||||||
U.S. treasury securities
|
|
|
(
|
)
|
|
|
|
|||||||||||||||||
|
|
(
|
)
|
|
|
|
||||||||||||||||||
Total
|
$
|
|
$
|
—
|
$
|
(50
|
)
|
$
|
|
$
|
|
$
|
|
December 31, 2020
|
||||||||||||||||||||||||
Adjusted
Cost |
Unrealized
Gains |
Unrealized
Losses |
Fair
Value |
Cash
and Cash Equivalents |
Investments
Available for Sale |
|||||||||||||||||||
Cash
|
$
|
|
$
|
—
|
$
|
—
|
$
|
|
$
|
|
$
|
—
|
||||||||||||
Level 1:
|
||||||||||||||||||||||||
Mutual funds
|
|
|
|
|
|
|
||||||||||||||||||
U.S. agency securities
|
|
|
|
|
|
|
||||||||||||||||||
U.S. treasury securities |
( |
) | ||||||||||||||||||||||
|
|
(
|
)
|
|
|
|
||||||||||||||||||
Total
|
$
|
|
$
|
2
|
$
|
(1
|
)
|
$
|
|
$
|
|
$
|
|
Item 9A. |
Controls and Procedures
|
Item 15. |
Exhibits and Financial Statement Schedules
|
(a)
|
The following documents are filed as part of this Annual Report on Form 10-K
|
(1) |
Financial Statements: See the Index to Consolidated Financial Statements under Item 8 of this Annual Report on Form 10-K.
|
(2) |
Financial Statement Schedule: Financial statement schedules are omitted because they are not applicable, or the required information is
shown in the financial statements or notes thereto. All other schedules are omitted because of the absence of conditions under which they are required or because the required information is given in the financial statements or the notes
thereto.
|
(3) |
Exhibits: The documents listed in the Exhibit Index of this Annual Report on Form 10-K are incorporated by reference or are filed with
this Annual Report on Form 10-K, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).
|
Exhibit
|
Incorporated by reference herein
|
||||
Number
|
Description
|
Form
|
Exhibit No.
|
Filing Date
|
File No.
|
3.1
|
8-K
|
3.1
|
11/01/2007
|
000-26895
|
|
3.2
|
8-K
|
3.2
|
11/01/2007
|
000-26895
|
|
4.1
|
S-1/A
|
4.1
|
01/16/2009
|
333-153645
|
|
4.2
|
8-K
|
4.1
|
09/03/2009
|
001-33852
|
|
4.3
|
S-3
|
4.1
|
07/30/2018
|
333-226413
|
|
4.4
|
S-3
|
4.2
|
07/30/2018
|
333-226413
|
|
4.5
|
S-3
|
4.4
|
07/30/2018
|
333-226413
|
|
4.6
|
10-K
|
4.6
|
03/16/2020
|
001-33852
|
|
10.1
|
10-K
|
10.1
|
03/18/2019
|
001-33852
|
|
10.2*
|
10-Q
|
10.2
|
05/10/2012
|
001-33852
|
|
10.3*
|
10-Q
|
4.5
|
05/10/2011
|
001-33852
|
|
10.4*
|
10-Q
|
10.3
|
05/10/2012
|
001-33852
|
|
10.5*
|
DEF 14A
|
Appendix A
|
04/13/2021
|
001-33852
|
|
10.6*
|
10-K
|
10.6
|
03/02/2015
|
001-33852
|
|
10.7*
|
10-K
|
10.7
|
03/02/2015
|
001-33852
|
|
10.8
|
10-K
|
10.11
|
03/31/2008
|
001-33852
|
|
10.9
|
8-K
|
10.1
|
09/03/2009
|
001-33852
|
|
10.10
|
8-K
|
10.2
|
09/03/2009
|
001-33852
|
|
10.11
|
S-1/A
|
1.1
|
01/16/2009
|
333-153645
|
|
10.12
|
8-K
|
10.4
|
07/12/2007
|
000-26895
|
|
10.13**
|
8-K
|
10.6
|
07/12/2007
|
000-26895
|
|
10.14
|
8-K
|
10.1
|
03/18/2008
|
001-33852
|
|
10.15
|
8-K
|
10.5
|
07/12/2007
|
000-26895
|
|
10.16
|
8-K
|
10.7
|
07/12/2007
|
000-26895
|
|
10.17
|
8-K
|
10.8
|
07/12/2007
|
000-26895
|
|
10.18**
|
10-Q/A
|
10.1
|
01/31/2011
|
001-33852
|
|
10.19**
|
10-K
|
10.23
|
03/02/2015
|
001-33852
|
10.20**
|
10-Q
|
10.1
|
11/09/2017
|
001-33852
|
|
10.21
|
10-Q
|
10.2
|
11/09/2017
|
001-33852
|
|
10.22
|
8-K
|
10.1
|
08/31/2018
|
001-33852
|
|
10.23*
|
10-Q
|
10.1
|
11/08/2021
|
001-33852
|
|
Consent of Farber Hass Hurley LLP, Independent Registered Public Accounting Firm.
|
|||||
Power of Attorney.
|
10-K |
24.1 |
3/16/2022 |
001-33852 |
|
Chief Executive Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act.
|
|||||
Chief Financial Officer Certification pursuant to Rule 13a-14(a) of the Securities Exchange Act.
|
|||||
Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002
|
|||||
Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of
2002.
|
|||||
101.INS
|
XBRL Instance Document
|
||||
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
||||
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
||||
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
||||
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
||||
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
||||
104
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
|
* |
Indicates management contract or compensatory plan.
|
** |
Confidential treatment has been granted by the SEC as to certain portions of this exhibit.
|
*** |
Portions of this exhibit have been omitted pending a determination by the SEC as to whether these portions should be granted confidential treatment.
|
† |
The certifications attached as Exhibit 32.1 and 32.2 that accompany this Report are not deemed filed with the Securities and Exchange Commission and are not to be incorporated
by reference into any filing of VirnetX Holding Corporation under the Securities Act or the Exchange Act, whether before or after the date of this Report, irrespective of any general incorporation language contained in such filing.
|
VirnetX Holding Corporation
|
||
By:
|
/s/ Kendall Larsen
|
|
Name: Kendall Larsen
|
||
Title: Chief Executive Officer and President
|
1. |
I have reviewed this Annual Report on Form 10-K/A of VirnetX Holding Corporation for the fiscal year ended December 31, 2021;
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of
the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the
registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and
the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant’s ability to record, process, summarize and report financial information; and
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/ Kendall Larsen
|
|
Kendall Larsen
|
|
President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
|
Date: May 13, 2022
|
1. |
I have reviewed this Annual Report on Form 10-K/A of VirnetX Holding Corporation for the fiscal year ended December 31, 2021;
|
2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of
the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
|
3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results
of operations and cash flows of the registrant as of, and for, the periods presented in this report;
|
4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
(a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information
relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
(b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable
assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
(c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
and procedures, as of the end of the period covered by this report based on such evaluation; and
|
(d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the
registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and
the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
|
(a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the
registrant’s ability to record, process, summarize and report financial information; and
|
(b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
/s/ Katherine Allanson
|
|
Katherine Allanson
|
|
Chief Financial Officer
|
|
(Principal Accounting and Financial Officer)
|
|
Date: May 13, 2022
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
|
/s/ Kendall Larsen
|
|
Kendall Larsen
|
|
President and Chief Executive Officer
|
|
(Principal Executive Officer)
|
|
Date: May 13, 2022
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
|
/s/ Katherine Allanson
|
|
Katherine Allanson
|
|
Chief Financial Officer
|
|
(Principal Accounting and Financial Officer)
|
|
Date: May 13, 2022
|